PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Vereide, D.T.* ; Seto, E. ; Chiu, Y.F.* ; Hayes, M.* ; Tagawa, T. ; Grundhoff, A.* ; Hammerschmidt, W. ; Sugden, B.*

Epstein-Barr virus maintains lymphomas via its miRNAs.

Oncogene 44, 1258-1264 (2014)
Publ. Version/Full Text DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
Epstein-Barr virus (EBV) has evolved exquisite controls over its host cells, human B lymphocytes, not only directing these cells during latency to proliferate and thereby expand the pool of infected cells, but also to survive and thereby persist for the lifetime of the infected individual. Although these activities ensure the virus is successful, they also make the virus oncogenic, particularly when infected people are immunosuppressed. Here we show, strikingly, that one set of EBV's microRNAs (miRNAs) both sustain Burkitt's lymphoma (BL) cells in the absence of other viral oncogenes and promote the transformation of primary B lymphocytes. BL cells were engineered to lose EBV and found to die by apoptosis and could be rescued by constitutively expressing viral miRNAs in them. Two of these EBV miRNAs were found to target caspase 3 to inhibit apoptosis at physiological concentrations.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
7.357
1.738
111
123
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords EBV; BART miRNAs; Apoptosis; RISC-IP; Burkitt's Lymphoma; Human Gamma-herpesviruses; Microrna Targets; Down-regulation; Lmp1 Oncogene; Protein; Ebv; Expression; Apoptosis; Cells; Bim
Language
Publication Year 2014
Prepublished in Year 2013
HGF-reported in Year 2013
ISSN (print) / ISBN 0950-9232
e-ISSN 0950-9232
Journal Oncogene
Quellenangaben Volume: 44, Issue: 10, Pages: 1258-1264 Article Number: , Supplement: ,
Publisher Nature Publishing Group
Publishing Place London
Reviewing status Peer reviewed
Institute(s) Research Unit Gene Vector (AGV)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-501500-001
DOI 10.1038/onc.2013.71
WOS ID WOS:000332631100006
Scopus ID 84895920376
PubMed ID 23503461
Erfassungsdatum 2013-08-02
[➜Report correction]